NCT06295341View on ClinicalTrials.gov

Short Stature and Psychological Well-being

CompletedOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Short StatureShort; Stature, Psychosocial
Interventions
DRUG

Recombinant human growth hormone (only for children with growth hormone deficiency)

6 months of therapy with recombinant DNA GH (at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).

Trial Locations (1)

20145

Istituto Auxologico Italiano, Milan

All Listed Sponsors
lead

Istituto Auxologico Italiano

OTHER

NCT06295341 - Short Stature and Psychological Well-being | Biotech Hunter | Biotech Hunter